The orthotopic implantation of human tumors in mice allows Xenopat to provide services focused on assisting anticancer drug development and personalized oncologic treatment. Xenopat’s services focus on two main fields:
Anticancer drug development.
Xenopat offers to researchers and companies devoted to the development of new anticancer drugs, the most innovative tools available nowadays. Xenopat offers these researchers the OrthoXenoBank®, composed of several orthotopic patient-derived xenografts (orthotopic PDXs, orthoxenografts®) of different tumor types, characterized at histological and genetic levels and with different sensitivity to diverse chemotherapies.
Personalized oncologic treatment.
Xenopat offers to healthcare professionals and patients the most advanced technology in order to select the best treatment in their fight against cancer. Xenopat offers the possibility to generate an orthoxenograft® from a small fragment of the patient’s tumor. This mouse model will allow Xenopat to test several drugs and find, the best therapy for each patient.
Company Details
- Employees
- 7
- Founded
- -
- Address
- C/feixa Llarga Sn. Edifici Bioincubadora., L'hospitalet De Llobregat,cataluña 08907,spain
- in****@****pat.com
- Industry
- Biotechnology
- Website
- xenopat.com
- Keywords
- Mouse models, Pre-clinical drug development, Patient-derived xenograft, Personalized medicine, Oncology.
- HQ
- L'Hospitalet de Llobregat, Cataluña
Xenopat Questions
Xenopat's website is xenopat.com
Xenopat's LinkedIn profile is https://es.linkedin.com/company/xenopat
Xenopat has
7 employees.
View email and phone details for 7
employees at Xenopat.
Xenopat's industry is
Biotechnology
Xenopat's top competitors are
Back To Battery,
Reig Jofre,
Neuro-Bio Ltd,
Nimble Diagnostics,
Parc Científic De Barcelona,
Onechain Immunotherapeutics,
Oncopeptides Ab (Publ),
Enantia,
Nanobots Therapeutics,
Kriba.
Xenopat's support email address is info@xenopat.com
Xenopat's categories are Biotechnology
Xenopat's founding year is 2014
